Progyny (NASDAQ:PGNY – Get Free Report) is set to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Progyny to post earnings of $0.37 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Progyny Trading Up 0.5 %
Progyny stock opened at $16.61 on Monday. Progyny has a 12 month low of $13.93 and a 12 month high of $42.08. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 1.57 and a beta of 1.44. The stock has a fifty day simple moving average of $18.14 and a two-hundred day simple moving average of $23.84.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on PGNY shares. Jefferies Financial Group dropped their price target on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, September 19th. Leerink Partnrs downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Leerink Partners lowered their price objective on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a research note on Thursday, September 19th. Finally, JPMorgan Chase & Co. reduced their price target on Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, September 19th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.73.
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Read More
- Five stocks we like better than Progyny
- What is a buyback in stocks? A comprehensive guide for investors
- California Resources Stock Could Be a Huge Long-Term Winner
- Basic Materials Stocks Investing
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- CD Calculator: Certificate of Deposit Calculator
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.